IRIDEX CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.84 USD | +1.43% |
|
-1.05% | +0.71% |
| Mar. 26 | Transcript : IRIDEX Corporation, Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | Earnings Flash (IRIX) IRIDEX CORPORATION Reports Q4 Revenue $12.5M, vs. Street Est of $14.9M | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +0.71% | 45.51M | - | ||
| +8.23% | 218B | B | ||
| +7.38% | 184B | B- | ||
| +13.36% | 135B | B- | ||
| -0.11% | 62.38B | A- | ||
| +12.13% | 51.37B | B+ | ||
| +4.81% | 50.9B | B+ | ||
| +0.63% | 40.87B | A | ||
| +2.38% | 36.28B | - | ||
| +26.35% | 31.88B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IRIX Stock
- Ratings IRIDEX Corporation